AbCellera Biologics Inc.

AbCellera Biologics Inc. is a biotechnology company focused on discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product candidate is ABCL635, a non-hormonal medicine currently in Phase 2 clinical trials for treating moderate-to-severe vasomotor symptoms. Another candidate, ABCL575, is a fully human, half-life extended monoclonal antibody in Phase 1 trials for T-cell-mediated autoimmune conditions such as atopic dermatitis. The company also has research collaborations with Eli Lilly and Company, AbbVie Inc., Jazz Pharmaceuticals plc, and Biogen Inc., and partnerships with Viking Global Investors and ArrowMark Partners.

AbCellera Biologics Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ABCL. Its shares trade in U.S. dollars (USD). The company is headquartered in Vancouver, Canada, but its stock is primarily traded on a U.S. exchange, providing access to a broad base of international investors.

AbCellera Biologics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative antibody-based therapies to address diseases with limited treatment options. The company's work involves advanced drug discovery and clinical development, targeting areas such as autoimmune conditions and women's health.

AbCellera Biologics is headquartered in Vancouver, Canada. While the company is based in Canada, its primary market focus is the United States, where it aims to address unmet medical needs through its antibody-based medicines. The company collaborates with global pharmaceutical partners such as Eli Lilly, AbbVie, Jazz Pharmaceuticals, and Biogen, indicating a reach that extends beyond North America through these partnerships.

AbCellera Biologics generates value through research collaborations and license agreements with major pharmaceutical companies. Notably, it has a research collaboration and license agreement with Eli Lilly and Company. Its portfolio also includes partnerships with AbbVie Inc. and Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies, as well as a partnership agreement with Viking Global Investors, ArrowMark Partners, and Biogen Inc. These collaborations provide funding, resources, and potential milestone payments, while AbCellera retains rights to its proprietary drug discovery platform and pipeline candidates.